On CNBC's “Mad Money Lightning Round,” Jim Cramer said AbbVie Inc. ABBV is doing “very, very well.” However, he added that Abbott Laboratories ABT remains his favorite in the group right now.
AbbVie was founded in 2013 when it became a separate company from Abbott.
On Oct. 9, UBS analyst Navin Jacob maintained AbbVie with a Neutral and raised the price target from $185 to $195.
When asked about Oracle ORCL, he said, “I like the prospects. But you're in it for the data center, and the data center business is excellent.”
Oracle recently launched Oracle Health Clinical Data Exchange, a cloud-based solution that streamlines medical claims processing through secure, automated data exchange between healthcare providers and payers.
Core Scientific, Inc. CORZ is a “mini-Palantir,” Cramer said. He recommended buying Palantir PLTR.
On Oct. 11, B. Riley Securities analyst Lucas Pipes maintained Core Scientific with a Buy and raised the price target from $13 to $14.
“I just don't want to go there. I know that it's a good company, but I just don't want to hurt anybody,” Cramer said when asked about Clover Health Investments, Corp. CLOV.
The company recent said the Centers for Medicare and Medicaid Services (CMS) increased the Star rating of its PPO Medicare Advantage plans to 4 Stars for 2025, affecting payments in 2026.
GXO Logistics GXO is a “very valuable company,” the “Mad Money” host said. “Just hold on.”
GXO recently announced a new transport partnership with Matalan.
Cramer said he really likes Sweetgreen, Inc. SG, adding that it is “terrific.”
Sweetgreen will release financial results for the third quarter after the closing bell on Thursday, Nov. 7.
Price Action:
- Oracle shares gained 0.4% to settle at $174.77 on Wednesday.
- AbbVie shares fell 0.7% to close at $190.46.
- Core Scientific shares gained 2.2% to close at $13.25 on Wednesday.
- GXO Logistics shares gained 2.6% to settle at $62.95.
- Sweetgreen shares fell 0.7% to close at $37.94 on Wednesday.
Read Next:
Image: Shutterstock
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.